Year: 2023
Type: dissertation
Abstract: Chimeric antigen receptor (CAR) T cells constitute an effective cancer \nimmunotherapy, yet several challenges remain. For example, although CD22 is a \npromising B-ALL target, selective pressure from CAR T cells reduces CD22 expression \nresulting in patient relapse. To circumvent this hurdle, I aimed to develop a module \nto improve CAR T cell sensitivity. CSK is an inhibitory kinase that negatively regulates \nT cell signalling. I envisioned that a dominant-negative CSK might improve CAR T cell \nsensitivity. Therefore, I engineered a number of dominant-negative iterations of CSK \n(dnCSK). The co-expression of dnCSK modules in different CAR T cell platforms was \nseen to enhance sensitivity, improving cytotoxicity and cytokine release (IFN-γ and \nIL-2) against low antigen density target cells. \nAnother challenge for CAR T cell therapies is on-target off-tumour toxicity. The \nsecond aim was to develop a module enabling tuneable control of CAR T cell function. \nTo do so, I employed a CSK mutant (CSKAS) that is inhibited by a PP1 analogue, 3-IBPP1. Co-expression of CSKAS in CD22 and GD2 targeting CAR T cells dampened CAR \nfunction in the absence of 3-IB-PP1. However, after the addition of 3-IB-PP1, both \nCD22 and GD2 targeting CAR T cells displayed improved function compared to control \nCAR T cells. An advantage of this approach is the lack of CAR architecture reengineering, permitting simple implementation into existing CAR platforms.
Author: Grothier, Thomas I
Institution: University College London
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6990824206
